News Releases

June 24, 2022
Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseases Eton’s royalty portfolio is now eligible to receive up to $70 million in
May 12, 2022
DEER PARK, Ill. , May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022 .
April 11, 2022
DEER PARK, Ill. , April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective
March 16, 2022
Fourth Quarter 2021 Revenue of $6.1 million Fourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill. , March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for